Efficacy and safety of brolucizumab in age‐related macular degeneration: A systematic review of real‐world studies-Reference-Cited by-同舟云学术

Efficacy and safety of brolucizumab in age‐related macular degeneration: A systematic review of real‐world studies

Published:2022-09-18 Issue:2 Volume:101 Page:123-139
ISSN:1755-375X
Container-title:Acta Ophthalmologica
language:en
Short-container-title:Acta Ophthalmologica

Author:

Baumal Caroline R.¹,Sørensen Torben Lykke²³^ORCID,Karcher Helene⁴,Freitas Rita L.⁵,Becher Anja⁶,Balez Sébastien⁷,Clemens Andreas⁴⁸,Singer Michael⁹,Kodjikian Laurent¹⁰

Affiliation:

1. New England Eye Center, Tufts Medical Center Boston Massachusetts USA

2. University of Copenhagen Copenhagen Denmark

3. Department of Ophthalmology Zealand University Hospital Roskilde Roskilde Denmark

4. Novartis Pharma AG Basel Switzerland

5. Novartis Farma – Produtos Farmacêuticos, S.A. Porto Salvo Portugal

6. Oxford PharmaGenesis Oxford UK

7. Novartis Pharma S.A.S. Rueil Malmaison France

8. Department of Cardiology and Angiology I, Heart Center Freiburg University, Faculty of Medicine University of Freiburg Freiburg Germany

9. University of Texas Health Science Center and Medical Center Ophthalmology San Antonio Texas USA

10. University of Lyon and Croix‐Rousse University Hospital UCBL, INSA Lyon, CNRS, MATEIS, UMR5510, Hospices Civils de Lyon Lyon France

Funder

Novartis Pharma

Publisher

Wiley

Subject

Ophthalmology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/aos.15242

Reference50 articles.

1. Abdin A.D. Aljundi W. Weinstein I. Aljawhari K. Suffo S.&Seitz B.(2021)Intravitreal brolucizumab for treatment of refractory macular edema due to neovascular age‐related macular deneration (real life data) (European Society of Retina Specialists [EURETINA] congress presentation).

2. A Global Assessment of Eye Health and Quality of Life

3. Real world efficacy and safety of brolucizumab in neovascular AMD: the REBEL study;Aziz A.A.;Investigative Ophthalmology & Visual Science,2021

4. Risk Factors for Intraocular Inflammation After Brolucizumab Treatment

5. Expert Opinion on Management of Intraocular Inflammation, Retinal Vasculitis, and Vascular Occlusion after Brolucizumab Treatment

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Investigating Flow-Induced Corrosion of Magnesium in Ophthalmological Milieu;Materials;2024-09-06

2. Long-acting delivery and therapies for neovascular age-related macular degeneration;Expert Opinion on Biological Therapy;2024-07-22

3. Comment on “Comparison of functional and morphologic changes between brolucizumab and faricimab in neovascular age-related macular degeneration”;Graefe's Archive for Clinical and Experimental Ophthalmology;2024-06-07

4. Real-World Weekly Efficacy Analysis of Faricimab in Patients with Age-Related Macular Degeneration;Bioengineering;2024-05-10

5. Real-World Safety Outcomes with Brolucizumab in Neovascular Age-Related Macular Degeneration: Findings from the IRIS® Registry;Ophthalmology and Therapy;2024-03-23